Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -2024202320222021202020192018201720162015 20 October 2022 Biocartis Announces First Drawdown of New Convertible Term Loans Regulated information 11 October 2022 Biocartis Announces Successful Amendment of its Existing Convertible Bonds Inside information Regulated information 10 October 2022 Biocartis Initiates Commercialization in Europe of HepatoPredict (CE-IVD) Test for Liver Cancer Patients Non-regulated information 27 September 2022 Invitation to the Extraordinary Shareholders’ Meeting Regulated information 26 September 2022 Biocartis Announces Launch of Amendment Process and Exchange Offer for its Existing Convertible Bonds Regulated information 6 September 2022 Disclosure of outstanding voting securities Regulated information 1 September 2022 BIOCARTIS ANNOUNCES H1 2022 RESULTS Regulated information 1 September 2022 Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma Patients Non-regulated information 1 September 2022 Biocartis Announces Entry into Comprehensive Recapitalization Arrangements to Strengthen Cash Position and Support Growth Inside information Regulated information 25 August 2022 Biocartis Announces 2022 Half-Year Results on 1 September 2022 Regulated information Pagination First page « First Previous page ‹‹ … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page ›› Last page Last »